FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890932482> ?p ?o ?g. }

• W2890932482 endingPage "2141" @default.
• W2890932482 startingPage "2131" @default.
• W2890932482 abstract "The influence of thrombocytopenia on the long-term clinical outcomes has not been thoroughly evaluated in patients with venous thromboembolism (VTE). This study sought to elucidate association of baseline thrombocytopenia with bleeding, recurrent VTE, and mortality risk. We evaluated the influence of baseline thrombocytopenia among 3,012 patients whose baseline platelet counts were available in the COMMAND VTE Registry in Japan with a median follow-up period of 1,219 days. Baseline thrombocytopenia was classified as follows: mild: 100,000 to 150,000/μl; moderate: 50,000 to 99,999/μl; and severe: <50,000/μl. The primary outcome measurement was International Society of Thrombosis and Hemostasis major bleeding, and the secondary outcome measurements were recurrent VTE and all-cause death. There were 167 patients (5.5%) with moderate or severe thrombocytopenia (moderate: 144 patients and severe: 23 patients), 523 patients (17.4%) with mild thrombocytopenia, and 2,322 patients (77.1%) without thrombocytopenia. The cumulative 5-year incidence of major bleeding was markedly higher in patients with moderate or severe thrombocytopenia (moderate or severe 29.4% vs mild: 14.1% vs no thrombocytopenia: 10.6%, p <0.001). After adjusting the confounders, the risk of or thrombocytopenia relative to no thrombocytopenia for major bleeding remained significant (adjusted hazard ratio [HR] 2.15, 95% confidence interval [CI] 1.43 to 3.13, p <0.001). The excess risk of moderate or severe thrombocytopenia relative to no thrombocytopenia was also significant for mortality (adjusted HR 1.54, 95% CI 1.18 to 1.97, p = 0.002), but the risk was neutral for recurrent VTE (adjusted HR 1.05, 95% CI 0.55 to 1.81, p = 0.87). In conclusion, VTE patients with baseline moderate or severe thrombocytopenia had higher risk for major bleeding events and mortality without significant excess risk for recurrent VTE events. The influence of thrombocytopenia on the long-term clinical outcomes has not been thoroughly evaluated in patients with venous thromboembolism (VTE). This study sought to elucidate association of baseline thrombocytopenia with bleeding, recurrent VTE, and mortality risk. We evaluated the influence of baseline thrombocytopenia among 3,012 patients whose baseline platelet counts were available in the COMMAND VTE Registry in Japan with a median follow-up period of 1,219 days. Baseline thrombocytopenia was classified as follows: mild: 100,000 to 150,000/μl; moderate: 50,000 to 99,999/μl; and severe: <50,000/μl. The primary outcome measurement was International Society of Thrombosis and Hemostasis major bleeding, and the secondary outcome measurements were recurrent VTE and all-cause death. There were 167 patients (5.5%) with moderate or severe thrombocytopenia (moderate: 144 patients and severe: 23 patients), 523 patients (17.4%) with mild thrombocytopenia, and 2,322 patients (77.1%) without thrombocytopenia. The cumulative 5-year incidence of major bleeding was markedly higher in patients with moderate or severe thrombocytopenia (moderate or severe 29.4% vs mild: 14.1% vs no thrombocytopenia: 10.6%, p <0.001). After adjusting the confounders, the risk of or thrombocytopenia relative to no thrombocytopenia for major bleeding remained significant (adjusted hazard ratio [HR] 2.15, 95% confidence interval [CI] 1.43 to 3.13, p <0.001). The excess risk of moderate or severe thrombocytopenia relative to no thrombocytopenia was also significant for mortality (adjusted HR 1.54, 95% CI 1.18 to 1.97, p = 0.002), but the risk was neutral for recurrent VTE (adjusted HR 1.05, 95% CI 0.55 to 1.81, p = 0.87). In conclusion, VTE patients with baseline moderate or severe thrombocytopenia had higher risk for major bleeding events and mortality without significant excess risk for recurrent VTE events." @default.
• W2890932482 created "2018-09-27" @default.
• W2890932482 creator A5001745348 @default.
• W2890932482 creator A5005311216 @default.
• W2890932482 creator A5012158016 @default.
• W2890932482 creator A5013223920 @default.
• W2890932482 creator A5016825334 @default.
• W2890932482 creator A5022030714 @default.
• W2890932482 creator A5023895524 @default.
• W2890932482 creator A5030952964 @default.
• W2890932482 creator A5031341593 @default.
• W2890932482 creator A5033861263 @default.
• W2890932482 creator A5036031425 @default.
• W2890932482 creator A5036972010 @default.
• W2890932482 creator A5042023852 @default.
• W2890932482 creator A5042834618 @default.
• W2890932482 creator A5043428080 @default.
• W2890932482 creator A5052975371 @default.
• W2890932482 creator A5060359833 @default.
• W2890932482 creator A5062835440 @default.
• W2890932482 creator A5063978809 @default.
• W2890932482 creator A5066001703 @default.
• W2890932482 creator A5066634844 @default.
• W2890932482 creator A5070724827 @default.
• W2890932482 creator A5074893258 @default.
• W2890932482 creator A5080185082 @default.
• W2890932482 creator A5082054042 @default.
• W2890932482 creator A5082150027 @default.
• W2890932482 creator A5083375651 @default.
• W2890932482 creator A5088920198 @default.
• W2890932482 creator A5090316816 @default.
• W2890932482 date "2018-12-01" @default.
• W2890932482 modified "2023-10-16" @default.
• W2890932482 title "Influence of Baseline Platelet Count on Outcomes in Patients With Venous Thromboembolism (from the COMMAND VTE Registry)" @default.
• W2890932482 cites W1508825876 @default.
• W2890932482 cites W1586488555 @default.
• W2890932482 cites W1598054478 @default.
• W2890932482 cites W1808477918 @default.
• W2890932482 cites W1964644585 @default.
• W2890932482 cites W1970988594 @default.
• W2890932482 cites W2010992436 @default.
• W2890932482 cites W2059244791 @default.
• W2890932482 cites W2065132155 @default.
• W2890932482 cites W2097561850 @default.
• W2890932482 cites W2102535207 @default.
• W2890932482 cites W2107941853 @default.
• W2890932482 cites W2120203545 @default.
• W2890932482 cites W2127985968 @default.
• W2890932482 cites W2160625453 @default.
• W2890932482 cites W2166361233 @default.
• W2890932482 cites W2168777811 @default.
• W2890932482 cites W2196194756 @default.
• W2890932482 cites W2225937646 @default.
• W2890932482 cites W2530960320 @default.
• W2890932482 cites W2792366458 @default.
• W2890932482 cites W2792827296 @default.
• W2890932482 cites W2989714602 @default.
• W2890932482 cites W4244303201 @default.
• W2890932482 cites W4296148784 @default.
• W2890932482 doi "https://doi.org/10.1016/j.amjcard.2018.08.053" @default.
• W2890932482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30293653" @default.
• W2890932482 hasPublicationYear "2018" @default.
• W2890932482 type Work @default.
• W2890932482 sameAs 2890932482 @default.
• W2890932482 citedByCount "10" @default.
• W2890932482 countsByYear W28909324822019 @default.
• W2890932482 countsByYear W28909324822020 @default.
• W2890932482 countsByYear W28909324822021 @default.
• W2890932482 crossrefType "journal-article" @default.
• W2890932482 hasAuthorship W2890932482A5001745348 @default.
• W2890932482 hasAuthorship W2890932482A5005311216 @default.
• W2890932482 hasAuthorship W2890932482A5012158016 @default.
• W2890932482 hasAuthorship W2890932482A5013223920 @default.
• W2890932482 hasAuthorship W2890932482A5016825334 @default.
• W2890932482 hasAuthorship W2890932482A5022030714 @default.
• W2890932482 hasAuthorship W2890932482A5023895524 @default.
• W2890932482 hasAuthorship W2890932482A5030952964 @default.
• W2890932482 hasAuthorship W2890932482A5031341593 @default.
• W2890932482 hasAuthorship W2890932482A5033861263 @default.
• W2890932482 hasAuthorship W2890932482A5036031425 @default.
• W2890932482 hasAuthorship W2890932482A5036972010 @default.
• W2890932482 hasAuthorship W2890932482A5042023852 @default.
• W2890932482 hasAuthorship W2890932482A5042834618 @default.
• W2890932482 hasAuthorship W2890932482A5043428080 @default.
• W2890932482 hasAuthorship W2890932482A5052975371 @default.
• W2890932482 hasAuthorship W2890932482A5060359833 @default.
• W2890932482 hasAuthorship W2890932482A5062835440 @default.
• W2890932482 hasAuthorship W2890932482A5063978809 @default.
• W2890932482 hasAuthorship W2890932482A5066001703 @default.
• W2890932482 hasAuthorship W2890932482A5066634844 @default.
• W2890932482 hasAuthorship W2890932482A5070724827 @default.
• W2890932482 hasAuthorship W2890932482A5074893258 @default.
• W2890932482 hasAuthorship W2890932482A5080185082 @default.
• W2890932482 hasAuthorship W2890932482A5082054042 @default.
• W2890932482 hasAuthorship W2890932482A5082150027 @default.
• W2890932482 hasAuthorship W2890932482A5083375651 @default.
• W2890932482 hasAuthorship W2890932482A5088920198 @default.
• W2890932482 hasAuthorship W2890932482A5090316816 @default.

• next